Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
Sponsor: Bristol-Myers Squibb
Summary
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration
Official title: A Phase 1, Open-label, Multi-part Study to Evaluate Pharmacokinetics, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 Following Intravenous and Subcutaneous Administrations in Healthy Adults and Multiple Doses of BMS-986446 in Participants With Early Alzheimer's Disease.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2026-08-21
Completion Date
2027-06-17
Last Updated
2026-09-24
Healthy Volunteers
Yes
Conditions
Interventions
BMS-986446
Specified dose on specified days
Locations (6)
CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
Anaheim, California, United States
Local Institution - 0003
Bradenton, Florida, United States
Local Institution - 0005
Daytona Beach, Florida, United States
Local Institution - 0007
Naples, Florida, United States
Local Institution - 0006
The Villages, Florida, United States
Local Institution - 0004
Decatur, Georgia, United States